DOD Amyotrophic Lateral Sclerosis, Clinical Outcomes and Biomarkers Award
ID: 353158Type: Posted
Overview

Buyer

Dept. of the Army -- USAMRAA (DOD-AMRAA)

Eligible Applicants

Unrestricted

Funding Category

Science and Technology and other Research and Development

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/353158
Timeline
    Description

    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the FY24 Amyotrophic Lateral Sclerosis Research Program (ALSRP) Clinical Outcomes and Biomarkers Award to support research aimed at developing and validating clinical outcomes and biomarkers for Amyotrophic Lateral Sclerosis (ALS). The program seeks innovative projects that can enhance clinical trials and patient care by focusing on specific therapies, ALS subtypes, and the integration of community perspectives in research planning and implementation. With an estimated total program funding of $6.1 million and a maximum budget of $750,000 per project, the initiative encourages applications from a wide range of organizations, including academic institutions and for-profit entities, with a two-step submission process that includes a Pre-Application due by June 18, 2024, and a full application by July 10, 2024. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.

    Point(s) of Contact
    help@eBRAP.org
    Files
    Title
    Posted
    HT942524ALSRPCOBA_GG2.pdf
    The Department of Defense (DOD) is announcing the FY24 Amyotrophic Lateral Sclerosis Research Program (ALSRP) Clinical Outcomes and Biomarkers Award aimed at fostering research to identify and validate clinical outcomes and biomarkers for Amyotrophic Lateral Sclerosis (ALS). The program emphasizes the development of innovative biomarkers and outcome measures related to ALS, potentially enhancing clinical trials and patient care. Applications must adhere to a two-step submission process involving a Pre-Application (Letter of Intent) by June 18, 2024, and a full application by July 10, 2024. Eligibility extends to both extramural and intramural organizations, including academic institutions and for-profit entities, and the maximum budget for funded projects is set at $750,000 with a performance period not exceeding three years. The announcement stresses meaningful community engagement with people who have ALS, emphasizing the role of community partners in research planning and implementation. Applications will be evaluated on scientific merit, research feasibility, clinical impact, and the integration of community perspectives. The initiative reflects a commitment to advancing ALS research through collaboration and innovative approaches that cater directly to the needs of ALS patients and their families.
    HT942524ALSRPCOBA.pdf
    Similar Opportunities
    Identify and Evaluate Potential Risk Factors for Amyotrophic Lateral Sclerosis (ALS)
    Centers for Disease Control and Prevention - ERA
    The Centers for Disease Control and Prevention (CDC) is inviting research proposals through a cooperative agreement to identify and evaluate potential risk factors for Amyotrophic Lateral Sclerosis (ALS). The opportunity encourages studies focusing on various aspects such as military service, contact sports, traumatic brain injury, neuroinflammation, and infectious agents, with four distinct funding options available to support both established and exploratory research. This initiative aims to enhance understanding of ALS risk factors, particularly in affected populations, and to analyze biological samples related to the Guamanian ALS cluster. Interested applicants can reach out to Dr. Candis Hunter at ncipcerpo@cdc.gov or by phone at 770-488-1347. The total estimated funding for this program is $7.5 million, with individual awards ranging from $0 to $500,000, and proposals are due by December 1, 2025, with awards expected to be announced by August 28, 2026.
    Studies Addressing Rare Neurodegenerative Diseases including ALS
    Food and Drug Administration
    The Food and Drug Administration (FDA) is forecasting a funding opportunity for studies addressing rare neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS). This grant aims to support research that advances the development of medical products intended to prevent, diagnose, mitigate, treat, or cure ALS and other rare neurodegenerative diseases in both adults and children. The initiative is crucial for addressing significant knowledge gaps in the field and is expected to have a substantial impact on the development of interventions for these conditions. Interested applicants can reach out to Terrin Brown at terrin.brown@fda.hhs.gov or by phone at 240-402-7610 for further information. The FDA anticipates awarding approximately 10 grants in fiscal year 2025, with no cost-sharing or matching requirements.
    DOD USAMRDC FY23-FY27 BROAD AGENCY ANNOUNCEMENT for Extramural Medical Research
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the U.S. Army Medical Research and Development Command (USAMRDC), has announced the FY23-FY27 Broad Agency Announcement (BAA) for Extramural Medical Research, which is open for submissions from October 1, 2022, to September 30, 2027. This opportunity invites innovative research proposals that address critical military medical challenges, particularly in the areas of Military Infectious Diseases, Combat Casualty Care, and Military Operational Medicine, with a focus on enhancing medical practices for both military personnel and civilians. The BAA emphasizes the importance of collaboration with Department of Defense and Department of Veterans Affairs resources and requires adherence to strict submission guidelines via Grants.gov and the electronic Biomedical Research Application Portal (eBRAP). Interested applicants can submit pre-proposals at any time during the five-year period, with full proposals invited based on initial submissions, and should direct inquiries to the CDMRP Help Desk at help@eBRAP.org.
    BROAD AGENCY ANNOUNCEMENT (BAA) for Extramural Biomedical and Human Performance Research and Development Department of Defense
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research Acquisition Activity (USAMRAA), has announced a Broad Agency Announcement (BAA) for Extramural Biomedical and Human Performance Research and Development. This opportunity invites unrestricted applicants to submit proposals aimed at advancing biomedical research and development, with a focus on enhancing human performance. The program is critical for fostering innovation in science and technology, particularly in areas that support the Department of Defense's mission. The estimated total program funding is $10 million, with individual awards ranging from $750,000 to $50 million, and proposals are due by July 31, 2028. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or by phone at 301-682-5507.
    Staff Research Program
    Dept of the Army -- Materiel Command
    The Department of the Army's Materiel Command is offering a funding opportunity for the Staff Research Program, aimed at engaging scientific staff in collaborative research with higher education institutions. This program seeks to enhance the professional competence of Army Research Office (ARO) scientists through hands-on, fundamental research in various scientific fields, including engineering, physical sciences, and life sciences, with a focus on advancing knowledge relevant to Army missions. Eligible applicants include institutions recognized for their scientific research capabilities, and the funding will be provided through cooperative agreements with award amounts ranging from $200,000 to $10 million. Proposals must be submitted via Grants.gov by June 2, 2030, and interested parties can contact Mr. William Creech at William.a.creech3.civ@army.mil for further information.
    Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Alzheimer's Drug-Development Program (Funding Opportunity Number: PAR-24-223), aimed at supporting the preclinical and early-stage clinical development of innovative drug candidates for Alzheimer's disease (AD). The program focuses on funding activities such as medicinal chemistry, pharmacokinetics, and Investigational New Drug (IND)-enabling studies, with the goal of advancing viable therapies to address the significant public health challenge posed by AD. Eligible applicants include a wide range of organizations, such as higher education institutions, nonprofits, and tribal organizations, with awards reaching up to $1.5 million over a period of up to five years for early-stage projects. Interested parties should submit their applications by November 5, 2027, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    NFRP Outreach and Invitation for Response
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research Acquisition Activity (USAMRAA), is forecasting an opportunity for a Research-based Other Transactions Agreement (rOTA) under the Neurofibromatosis Research Program (NFRP). This initiative aims to accelerate the clinical translation of basic research related to neurofibromatosis (NF) by conducting collaborative Phase I and II clinical trials focused on promising therapeutic agents for NF1, NF2, and schwannomatosis. Historically, this requirement has been addressed through assistance agreements, and the government is now seeking feedback on this proposed approach, emphasizing the need for cost-sharing arrangements and access to patient populations. Interested parties can direct inquiries to Jason D. Kuhns at jason.d.kuhns.civ@mail.mil, with the opportunity being part of the FY21 portfolio and requiring a demonstrated history of collaborative research among participants.
    Small Research Grant Program for the Next Generation of Researchers in AD/ADRD Research (R03 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Aging (NIA), is offering a Small Research Grant Program (R03) aimed at fostering the next generation of researchers in Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). This program supports innovative projects that enhance understanding, diagnosis, treatment, and care strategies for AD/ADRD, while also promoting workforce diversity and addressing health disparities in this field. Grants of up to $100,000 for a duration of two years are available, with a total of 12 awards expected for fiscal year 2024, amounting to $1.8 million in funding. Interested applicants must be affiliated with eligible organizations and are encouraged to submit their applications by March 16, 2026, with inquiries directed to grantsinfo@nih.gov for further information.
    Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U44 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the clinical validation of candidate biomarkers for neurological and neuromuscular disorders through the U44 Cooperative Agreement mechanism. This initiative aims to rigorously validate biomarkers that have already been identified and for which detection methods have been developed, ensuring compliance with FDA guidelines to establish their clinical sensitivity and specificity. This program is crucial for advancing therapeutic development in the field of brain health, with funding potentially reaching $700,000 for Phase I and $1.5 million for Phase II projects. Interested applicants must adhere to specific submission guidelines and deadlines, with the application closing on June 22, 2026. For further information, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-24-096.html.
    Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Alzheimer's Drug-Development Program (U01 Clinical Trial Optional) to support the preclinical and early-stage clinical development of innovative drug candidates aimed at preventing or treating Alzheimer's disease (AD). This funding opportunity focuses on activities such as medicinal chemistry, pharmacokinetics, formulation development, and initial Phase I clinical testing, addressing the urgent public health challenge posed by AD, which currently affects approximately 6.7 million individuals in the U.S. Eligible applicants include a diverse range of organizations, with a funding ceiling of $1.5 million per year, and the application process is set to begin in January 2025, with a closing date of November 5, 2027. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.